Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ruxandra Julia Vorovenci"'
Autor:
Ruxandra Julia Vorovenci, Mihaela Simu, Cristina Bejinar, Inge Krabbendam, Amalia M. Dolga, Ioan Ovidiu Sirbu, Cristina Dijmarescu, Cecilia Rosca, Aimee Rodica Chis, Catalin Marian, Alexandra Ioana Moatar
Publikováno v:
Journal of Cellular and Molecular Medicine
Journal of cellular and molecular medicine, 25(18), 8715-8724. Wiley
Journal of cellular and molecular medicine, 25(18), 8715-8724. Wiley
Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs. LevoDopa replacement is the gold standard therapy for PD, as it ameliorates the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::422f4bd45a01e02203e07b405af972db
https://doi.org/10.1111/jcmm.16827
https://doi.org/10.1111/jcmm.16827
Autor:
Tiziano Tamburini, Alessandra Nicoletti, Ruxandra Julia Vorovenci, Angelo Antonini, Angela Matinella, Leonardo Lopiano, Francesca Morgante, Pietro Cortelli, Giovanna Calandra-Buonaura, Luca Weis, Michele Tinazzi, Mario Zappia, Maria Cristina Jori, Roberta Biundo, Roberto Marconi, Giovanni Abbruzzese
Publikováno v:
Movement Disorders. 32:1557-1565
Background Impulse control disorders and dyskinesia are common and disabling complications of dopaminergic treatment in Parkinson's disease. They may coexist and are possibly related. The objectives of this study were to assess the frequency and seve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd2f263316c33a416c58cb7b62b9dc6f
https://doi.org/10.1002/mds.27181
https://doi.org/10.1002/mds.27181
Publikováno v:
Expert Review of Neurotherapeutics. 15:1383-1390
The moderate and severe stages of Parkinson's disease (PD) are marked by motor and non-motor complications that still remain difficult to control with the currently available therapy. Adenosine A(2A) receptor antagonists target non-dopaminergic syste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4669070d127a881dc8bf6d1511e4363
https://doi.org/10.1586/14737175.2015.1113131
https://doi.org/10.1586/14737175.2015.1113131
Autor:
Ligia Petrica, Ruxandra Julia Vorovenci, Romulus Timar, Bogdan Timar, Flaviu Bob, Adalbert Schiller, Adelina Mihaescu, Cristina Gluhovschi, Silvia Velciov, Mihaela Simu, Goce Spasovski, Raluca Tudor, Florina Parv, Viviana Ivan, Florica Gadalean
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 10, p e0185589 (2017)
PLoS ONE, Vol 12, Iss 10, p e0185589 (2017)
Introduction Acute kidney injury (AKI) increases the risk of death in acute ischemic stroke (AIS) patients. Intravenous thrombolytic therapy (iv. rt-PA) seems to be the most effective treatment for AIS patients. The effects of AKI on iv. rt-PA treate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4dcf96fedd4c4c6533997f8d3f8dff7
https://pubmed.ncbi.nlm.nih.gov/29040276
https://pubmed.ncbi.nlm.nih.gov/29040276
In recent years, the management of Parkinson's disease (PD) has come a long way, leading to an increase in therapeutic options that now include oral and transdermal drug delivery, infusion as well as surgical treatments. Nonetheless, in the evolution
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a625c8a9e8bc7944996b44db03ac16be
http://hdl.handle.net/11577/3232881
http://hdl.handle.net/11577/3232881
Publikováno v:
Resuscitation. 96:155
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c04ad3493660fecdeed57ea3b9dbcf39
https://doi.org/10.1016/j.resuscitation.2015.09.372
https://doi.org/10.1016/j.resuscitation.2015.09.372